These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 37838149)
1. Protein binding investigation of first-line and second-line antituberculosis drugs. Fage D; Aalhoul F; Cotton F Int J Antimicrob Agents; 2023 Dec; 62(6):106999. PubMed ID: 37838149 [TBL] [Abstract][Full Text] [Related]
2. Protein Binding of First-Line Antituberculosis Drugs. Alghamdi WA; Al-Shaer MH; Peloquin CA Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735566 [TBL] [Abstract][Full Text] [Related]
3. Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure. Mushtaq F; Raza SM; Ahmad A; Aslam H; Adeel A; Saleem S; Ahmad I PLoS One; 2023; 18(10):e0293194. PubMed ID: 37883448 [TBL] [Abstract][Full Text] [Related]
4. Development, validation and clinical use of a LC-MS/MS method for the simultaneous determination of the nine main antituberculosis drugs in human plasma. Fage D; Brilleman R; Deprez G; Payen MC; Cotton F J Pharm Biomed Anal; 2022 Jun; 215():114776. PubMed ID: 35462286 [TBL] [Abstract][Full Text] [Related]
6. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Williams KN; Stover CK; Zhu T; Tasneen R; Tyagi S; Grosset JH; Nuermberger E Antimicrob Agents Chemother; 2009 Apr; 53(4):1314-9. PubMed ID: 19075058 [TBL] [Abstract][Full Text] [Related]
7. Antituberculosis drug prescribing for inpatients in a national tuberculosis hospital in China, 2011-2015. An J; Bai X; Gao M; Chu N; Huang H; Xu H; Zhang X; Li B; Huang C; Cai H; Zhang F; Pang Y; Li L J Glob Antimicrob Resist; 2018 Sep; 14():17-22. PubMed ID: 29476986 [TBL] [Abstract][Full Text] [Related]
8. Combinatory activity of linezolid and levofloxacin with antituberculosis drugs in Mycobacterium tuberculosis. Santos NCS; Scodro RBL; de Almeida AL; Baldin VP; Nakamura de Vasconcelos SS; Siqueira VLD; Caleffi-Ferracioli KR; Campanerut-Sá PAZ; Cardoso RF Tuberculosis (Edinb); 2018 Jul; 111():41-44. PubMed ID: 30029913 [TBL] [Abstract][Full Text] [Related]
9. Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19. Tahseen S; Khanzada FM; Rizvi AH; Qadir M; Ghazal A; Baloch AQ; Mustafa T PLoS One; 2020; 15(9):e0239328. PubMed ID: 32966321 [TBL] [Abstract][Full Text] [Related]
10. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Rullas J; García JI; Beltrán M; Cardona PJ; Cáceres N; García-Bustos JF; Angulo-Barturen I Antimicrob Agents Chemother; 2010 May; 54(5):2262-4. PubMed ID: 20160054 [TBL] [Abstract][Full Text] [Related]
11. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. ; Allix-Béguec C; Arandjelovic I; Bi L; Beckert P; Bonnet M; Bradley P; Cabibbe AM; Cancino-Muñoz I; Caulfield MJ; Chaiprasert A; Cirillo DM; Clifton DA; Comas I; Crook DW; De Filippo MR; de Neeling H; Diel R; Drobniewski FA; Faksri K; Farhat MR; Fleming J; Fowler P; Fowler TA; Gao Q; Gardy J; Gascoyne-Binzi D; Gibertoni-Cruz AL; Gil-Brusola A; Golubchik T; Gonzalo X; Grandjean L; He G; Guthrie JL; Hoosdally S; Hunt M; Iqbal Z; Ismail N; Johnston J; Khanzada FM; Khor CC; Kohl TA; Kong C; Lipworth S; Liu Q; Maphalala G; Martinez E; Mathys V; Merker M; Miotto P; Mistry N; Moore DAJ; Murray M; Niemann S; Omar SV; Ong RT; Peto TEA; Posey JE; Prammananan T; Pym A; Rodrigues C; Rodrigues M; Rodwell T; Rossolini GM; Sánchez Padilla E; Schito M; Shen X; Shendure J; Sintchenko V; Sloutsky A; Smith EG; Snyder M; Soetaert K; Starks AM; Supply P; Suriyapol P; Tahseen S; Tang P; Teo YY; Thuong TNT; Thwaites G; Tortoli E; van Soolingen D; Walker AS; Walker TM; Wilcox M; Wilson DJ; Wyllie D; Yang Y; Zhang H; Zhao Y; Zhu B N Engl J Med; 2018 Oct; 379(15):1403-1415. PubMed ID: 30280646 [TBL] [Abstract][Full Text] [Related]
12. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076 [TBL] [Abstract][Full Text] [Related]
13. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904 [TBL] [Abstract][Full Text] [Related]
14. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Grace AG; Mittal A; Jain S; Tripathy JP; Satyanarayana S; Tharyan P; Kirubakaran R Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012918. PubMed ID: 31828771 [TBL] [Abstract][Full Text] [Related]
15. [Epidural abscess due to a Mycobacterium tuberculosis strain with primary resistance to isoniazid and ethambutol]. Sener A; Akçalı A; Karatağ O; Koşar S; Değirmenci Y; Akman T Mikrobiyol Bul; 2012 Oct; 46(4):689-94. PubMed ID: 23188583 [TBL] [Abstract][Full Text] [Related]
16. Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics. Wilkinson D; Pillay M; Davies GR; Sturm AW Trans R Soc Trop Med Hyg; 1996; 90(6):692-5. PubMed ID: 9015521 [TBL] [Abstract][Full Text] [Related]
17. A Multilaboratory, Multicountry Study To Determine MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing of Selected First-Line Antituberculosis Drugs, Second-Line Injectables, Fluoroquinolones, Clofazimine, and Linezolid. Kaniga K; Cirillo DM; Hoffner S; Ismail NA; Kaur D; Lounis N; Metchock B; Pfyffer GE; Venter A J Clin Microbiol; 2016 Dec; 54(12):2963-2968. PubMed ID: 27654338 [TBL] [Abstract][Full Text] [Related]
18. Determination of minimum bactericidal concentration, in single or combination drugs, against Santos NCS; Scodro RBL; Leal DC; do Prado SM; Micheletti DF; Sampiron EG; Costacurta GF; de Almeida AL; da Silva LA; Ieque AL; Ghiraldi Lopes LD; de Pádua RA; Siqueira VL; Caleffi-Ferracioli KR; Cardoso RF Future Microbiol; 2020 Jan; 15():107-114. PubMed ID: 32064924 [No Abstract] [Full Text] [Related]
19. Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. Denti P; Wasmann RE; van Rie A; Winckler J; Bekker A; Rabie H; Hesseling AC; van der Laan LE; Gonzalez-Martinez C; Zar HJ; Davies G; Wiesner L; Svensson EM; McIlleron HM Clin Infect Dis; 2022 Aug; 75(1):141-151. PubMed ID: 34665866 [TBL] [Abstract][Full Text] [Related]
20. Pretomanid for tuberculosis: a systematic review. Gils T; Lynen L; de Jong BC; Van Deun A; Decroo T Clin Microbiol Infect; 2022 Jan; 28(1):31-42. PubMed ID: 34400340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]